Stock Price Forecast

March 27, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading UroGen Pharma Ltd chart...

About the Company

urogen pharma ltd. (nasdaq:urgn) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. the company has developed rtgel™, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. urogen pharma's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. urogen pharma's lead product candidates, mitogel™ (mitomycin urothelial gel) and vesigel™ (mitomycin intravesical gel), are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma and bladder cancer, respectively. urogen pharma is headquartered in ra’anana, israel with u.s. headquarters in new york.

CEO

Elizabeth Barrett

Exchange

NASDAQ

Website

http://www.urogen.com

$82M

Total Revenue

206

Employees

$486M

Market Capitalization

-2.45

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $URGN News

UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2023 Earnings Call Transcript

13d ago, source:

Q4 2023 Earnings Call March 14, 2024 UroGen Pharma Ltd. isn’t one of the 30 most popular stocks among hedge funds at the end ...

URGN Stock Earnings: UroGen Pharma Misses EPS, Beats Revenue for Q4 2023

on MSN ago, source:

URGN stock results show that UroGen Pharma missed analyst estimates for earnings per share but beat on revenue for the fourth ...

UroGen Pharma Ltd (URGN) Reports Solid JELMYTO Growth Amidst Financial Challenges

14d ago, source: Yahoo Finance

Warning! GuruFocus has detected 6 Warning Signs with URGN. On March 14, 2024, UroGen Pharma Ltd (NASDAQ:URGN) released its 8-K filing, detailing the financial results for the fourth quarter and ...

UroGen Pharma Ltd URGN

13d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102

14d ago, source: Stockhouse

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for ...

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

20d ago, source: Stockhouse

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of ...

UroGen Pharma reports mixed Q4 results; initiates FY24 outlook

on MSN ago, source:

Q4 GAAP EPS of -$0.72 misses by $0.03. Revenue of $23.5M (+29.9% Y/Y) beats by $0.93M. As of December 31, 2023, cash, cash equivalents and ...

UroGen Pharma Ltd.

28d ago, source: Wall Street Journal

Earnings Per Share (TTM) A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. Market Capitalization Reflects the total ...

UroGen Pharma Ltd (URGN) Reports Solid JELMYTO Growth Amidst Financial Challenges

14d ago, source: Yahoo Finance

Warning! GuruFocus has detected 6 Warning Signs with URGN. On March 14, 2024, UroGen Pharma Ltd (NASDAQ:URGN) released its ...

UroGen Pharma Delivers Double Digit JELMYTO Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102

14d ago, source: Finanznachrichten

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...